EGFR and metastatic neoplasm: This illustrates ACTL’s potential to remodel the tumor immune milieu and overcome osimertinib resistance of undefined etiology, in contrast to immune-checkpoint inhibitors, which show limited activity in EGFR-mutant advanced NSCLC but confer clear benefit in EGFR-wild-type metastatic disease[108].